Aumed, a.s., Komořanská 326/63, 143 14 Praha - Modřany, Česká republika

info@aumed.cz+420 603 587 701 English

Oral vaccine administration

Research and development of a new administration of the vaccine in the company AUMED, a.s.

AUMED, a.s. started active cooperation with the Charles University, Faculty of Pharmacy in Hradec Králové on the development of a new vaccine which will be administered orally as a lyophilized tablet. A newly innovated pertussis vaccine has been chosen as a model vaccine which was developed by the company AUMED, a.s. in recent years. The chosen model vaccine is justified in the increasing number of local epidemics of whooping cough.

WHY RESEARCH IN THIS AREA?

Previously used vaccines are injected as a classical parenteral drug. The vaccine application induces the immune response of the organism, but the disadvantage is the reduced protective effect on nasopharynx mucosa, which is the entry gate of infection. Oral administration of Bordetella pertussis vaccine is technically justified because the mucosal immune system of the oral cavity and nasopharynx are interconnected. The immune response to this form of administration is supported by clinical tests. The lyophilized tablet, as a new form of vaccine, guarantees a satisfactory distribution on the buccal mucosa. The trend of using lyophilized tablets as a new drug form is generally accepted in pharmaceutical application and is understood to be a progressive solution.

AIM OF OUR RESEARCH

These research activities should result in a microbial vaccine in the form of a lyophilized tablet administered orally.

This project is implemented with the financial support of the state budget through the Ministry of Industry and Trade in the TRIO program

Research projects of Aumed, a.s. are financed by the European Structural Funds:
Research and development of a new pertussis vaccine
Transfer factor — research and development of a new medical form
Production of diagnostic kit for covid-19 on the lamp principle

and with financial support from the state budget through the Ministry of Industry and Trade in the TRIO program:
Research and development of a new oral administration of vaccine

European Union
European Regional Development Fund
OP Enterprise and Innovation for Competitiveness


Tel.: +420 603 587 701, Email: info@aumed.cz
Komořanská 326/63, 143 14 Praha - Modřany, Česká republika
(c) 2017, Aumed a.s